Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to $171.7 million.

  • Agilon Health's Cash & Equivalents rose 1587.66% to $171.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.7 million, marking a year-over-year increase of 1587.66%. This contributed to the annual value of $188.2 million for FY2024, which is 7498.47% up from last year.
  • As of Q3 2025, Agilon Health's Cash & Equivalents stood at $171.7 million, which was up 1587.66% from $171.4 million recorded in Q2 2025.
  • Agilon Health's 5-year Cash & Equivalents high stood at $1.1 billion for Q2 2021, and its period low was $105.3 million during Q1 2021.
  • For the 5-year period, Agilon Health's Cash & Equivalents averaged around $418.0 million, with its median value being $188.2 million (2024).
  • In the last 5 years, Agilon Health's Cash & Equivalents soared by 87386.49% in 2021 and then plummeted by 7688.17% in 2023.
  • Quarter analysis of 5 years shows Agilon Health's Cash & Equivalents stood at $1.0 billion in 2021, then plummeted by 55.26% to $465.3 million in 2022, then plummeted by 76.88% to $107.6 million in 2023, then skyrocketed by 74.98% to $188.2 million in 2024, then decreased by 8.79% to $171.7 million in 2025.
  • Its last three reported values are $171.7 million in Q3 2025, $171.4 million for Q2 2025, and $136.9 million during Q1 2025.